MENU
+Compare
SONN
Stock ticker: NASDAQ
AS OF
Feb 21 closing price
Price
$1.44
Change
+$0.01 (+0.70%)
Capitalization
4.41M

SONN Sonnet BioTherapeutics Holdings Inc Forecast, Technical & Fundamental Analysis

a company, which engages in the development of biologic drugs with enhanced single or bispecific mechanisms

Industry Biotechnology
SONN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for SONN with price predictions
Feb 18, 2025

SONN in -3.05% downward trend, declining for three consecutive days on February 07, 2025

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where SONN declined for three days, in of 400 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on February 05, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on SONN as a result. In of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

SONN broke above its upper Bollinger Band on January 22, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SONN advanced for three days, in of 193 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.094) is normal, around the industry mean (12.604). P/E Ratio (0.288) is within average values for comparable stocks, (85.387). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.581). SONN has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (1.501) is also within normal values, averaging (252.111).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. SONN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SONN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
SONN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

SONN is expected to report earnings to rise 3,061.54% to -411 cents per share on November 29

Sonnet BioTherapeutics Holdings Inc SONN Stock Earnings Reports
Q3'23
Est.
$-4.11
Q2'23
Beat
by $0.16
Q1'23
Missed
by $6.99
Q4'22
Beat
by $0.33
Q3'22
Missed
by $35.23
The last earnings report on August 14 showed earnings per share of -12 cents, beating the estimate of -28 cents. With 67.88K shares outstanding, the current market capitalization sits at 4.41M.
A.I. Advisor
published General Information

General Information

a company, which engages in the development of biologic drugs with enhanced single or bispecific mechanisms

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
100 Overlook Center
Phone
+1 609 375-2227
Employees
12
Web
https://www.sonnetbio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPY611.491.79
+0.29%
SPDR® S&P 500® ETF Trust
AAPL244.47-0.13
-0.05%
Apple
GME26.97-0.03
-0.11%
GameStop Corp
BTC.X95539.550000-233.835940
-0.24%
Bitcoin cryptocurrency
TSLA354.11-1.73
-0.49%
Tesla

SONN and Stocks

Correlation & Price change

A.I.dvisor tells us that SONN and SNBIF have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SONN and SNBIF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SONN
1D Price
Change %
SONN100%
-3.77%
SNBIF - SONN
28%
Poorly correlated
N/A
NTLA - SONN
27%
Poorly correlated
+7.76%
PRME - SONN
27%
Poorly correlated
+5.28%
CHRS - SONN
26%
Poorly correlated
-5.08%
ABCL - SONN
26%
Poorly correlated
+4.89%
More